Progress in cancer therapy targeting c-Met signaling pathway

Archives of Pharmacal Research
Kyung Hee JungSoon-Sun Hong

Abstract

A primary hurdle in developing anticancer therapeutics is to selectively target cancer cells while sparing normal tissues. Oncogenic protein kinases represent a class of biologically important targets for cancer intervention. Among them, c-Met is a receptor tyrosine kinase (RTK) that has low activity in normal tissues but is dysregulated in many tumor types. The c-Met is the prototype member of a subfamily of RTKs, which includes Ron, which is structurally distinct from other RTK families. It is the only known high-affinity receptor for hepatocyte growth factor, also known as scatter factor. HGF and c-Met are both required for normal mammalian development. In adults, both are widely expressed in a variety of tissues; however, their expression is normally very low and is involved mainly in tissue damage, repair and regeneration. The results of in vitro and in vivo experiments have shown that this receptor-growth factor pair is involved in multiple physiologic cellular responses, including cell proliferation, survival, differentiation, motility, and invasion. Here, as well as presenting the biological aspects of c-Met signaling regulation, we consider recent findings that have provided new knowledge at the molecular, cellular, an...Continue Reading

References

Aug 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·K M WeidnerY Daikuhara
Jul 19, 1990·Nature·E Gherardi, M Stoker
Jan 1, 1993·Advances in Cancer Research·G Kovacs
May 15, 1997·The EMBO Journal·G A RodriguesJ Schlessinger
Oct 28, 1998·Trends in Cell Biology·C Birchmeier, E Gherardi
Nov 25, 1998·Proceedings of the National Academy of Sciences of the United States of America·A BardelliP M Comoglio
Jun 29, 2000·Oncogene·A FollenziP M Comoglio
Jan 23, 2002·Oncogene·Yu-Wen ZhangGeorge F Vande Woude
Dec 20, 2003·Nature Reviews. Molecular Cell Biology·Carmen BirchmeierGeorge F Vande Woude
Jul 21, 2004·Cancer Cell·Paolo MichieliPaolo M Comoglio
Jul 21, 2004·Cancer Cell·Monica Kong-BeltranDineli Wickramasinghe
Nov 17, 2004·The Journal of Clinical Investigation·Massimiliano MazzonePaolo Michieli
Nov 19, 2004·Molecular Biology of the Cell·Hanane KhouryMorag Park
May 5, 2005·Molecular and Cellular Biology·M Cristina StellaPaolo M Comoglio
Jun 14, 2005·Biochemical and Biophysical Research Communications·Kunio Matsumoto, Toshikazu Nakamura
Feb 8, 2006·Proceedings of the National Academy of Sciences of the United States of America·Gromoslaw A SmolenDaniel A Haber
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·K Jin KimJohn Laterra
Mar 21, 2006·Proceedings of the National Academy of Sciences of the United States of America·Annalisa PetrelliSilvia Giordano
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tobias MartensKatrin Lamszus
Mar 9, 2007·Nature·Christopher GreenmanMichael R Stratton
Oct 19, 2007·The New England Journal of Medicine·Michalis V KaramouzisAthanasios G Papavassiliou
Nov 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·H Toni JunTeresa L Burgess
Dec 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·James BeanWilliam Pao
Apr 15, 2008·Current Opinion in Genetics & Development·Beatrice S Knudsen, George Vande Woude
May 31, 2008·Nature Reviews. Drug Discovery·Paolo M ComoglioLivio Trusolino
Jun 14, 2008·Expert Opinion on Investigational Drugs·Xiangdong LiuPeggy A Scherle
Aug 19, 2008·Genes, Chromosomes & Cancer·Patrick C MaRavi Salgia
Mar 13, 2009·CA: a Cancer Journal for Clinicians·Wen W Ma, Alex A Adjei
Dec 18, 2009·Anti-cancer Agents in Medicinal Chemistry·Fadila GuessousRoger Abounader
Dec 25, 2009·Trends in Molecular Medicine·Xiangdong LiuPeggy A Scherle
May 18, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joseph Paul EderPatricia M LoRusso
Nov 26, 2010·Nature Reviews. Molecular Cell Biology·Livio TrusolinoPaolo M Comoglio

❮ Previous
Next ❯

Citations

May 25, 2013·European Journal of Medicinal Chemistry·Lianbao YeShuguang Wu
Sep 13, 2012·PloS One·Assaf ZaritskyIlan Tsarfaty
Jun 7, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·O F OlmezO Manavoglu
Aug 3, 2014·Advanced Drug Delivery Reviews·Hao HongWeibo Cai
Dec 10, 2015·International Journal of Endocrinology·Lifeng NingQiong Yu
Jul 5, 2015·Life Sciences·Zhiming WuChaoyang Xu
May 21, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Andrew Timm, Jill M Kolesar
Jun 7, 2015·Archives of Pharmacal Research·Faisal HayatDongyun Shin
Mar 26, 2016·Oncotarget·Yanni ZhangMingqiang Zhang
Jul 21, 2020·Journal of Cellular and Molecular Medicine·Evangelos KoustasAthanasios G Papavassiliou
Jan 22, 2015·Biomedicines·Anna SpinaLuigi Michele Pavone
May 1, 2021·Cancers·Malak SabbahGhanem E Ghanem
Dec 21, 2018·Journal of Medicinal Chemistry·Vishnu C DamalankaJames W Janetka
Nov 19, 2021·Expert Opinion on Therapeutic Patents·Cilong ChuWufu Zhu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Related Papers

Nature Reviews. Cancer
Ermanno GherardiG F Vande Woude
Annual Review of Pathology
Marina Bacac, Ivan Stamenkovic
Journal of Cellular Physiology
Silvia Benvenuti, Paolo M Comoglio
© 2021 Meta ULC. All rights reserved